JAHA reports that starting vericiguat at hospital discharge for acute heart failure was associated with large reductions in 180-day readmission and improved NYHA class with favorable safety signals.
Starting vericiguat at hospital discharge for acute HF led to a 57% reduction in 180-day readmission and NYHA improvement, with favorable safety and tolerability profiles.
led to a 57% reduction in 180-day readmission
favorable safety and tolerability profiles
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare